The global T-cell Lymphoma Market is estimated to be valued at US$ 1961.64 Mn or Mn in 2023 and is expected to exhibit a CAGR of 9.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
T-cell Lymphoma is a blood cancer that affects the T cells, a type of white blood cells that fight infections. T-cell Lymphoma treatments include radiation therapy, chemotherapy, targeted therapy and stem cell transplantation. These treatments help patients fight cancer and live longer.
Market key trends:
Rising incidence of T-cell Lymphoma is one of the key trends driving the growth of this market. According to Cancer Research UK, there were around 2,150 new cases of T-cell Lymphoma in UK in 2020. Increasing awareness about early diagnosis and availability of advanced treatment options are also fueling the market growth. Growing research in immunotherapy and targeted drugs is expected to create new opportunities over the forecast period.
Strength: T-cell Lymphoma has a high unmet medical need as there are limited treatment options available. Increasing focus on R&D of novel therapies and immunotherapies provides opportunities.
Weakness: Low diagnosis rate due to lack of early detection methods and symptoms mimicking other conditions. High cost of treatment poses affordability challenges.
Opportunity: Increasing approval and launches of pipeline drugs like mogamulizumab, lenalidomide offers new treatment options. Growing awareness regarding blood cancers also helps in early diagnosis.
Threats: Slow adoption of novel therapies due to high prices can impede market growth. Stringent regulations for drug approvals also delays market entry of new drugs.
The global T-cell Lymphoma market size is expected to witness high growth, exhibiting CAGR of 9.8% over the forecast period, due to increasing research and development of novel therapies.
Regional analysis: North America is expected to dominate the global T-cell Lymphoma market over the forecast period owing to rising incidence of blood cancers, availability of advanced treatment options and high healthcare expenditure. Asia Pacific will witness fastest growth due to growing healthcare infrastructure and increasing patient affordability.
Key players operating in the T-cell Lymphoma market are F. Hoffmann-La Roche Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG, SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health Companies Inc.